Back to top
more

Novo Nordisk (NVO)

(Delayed Data from NYSE)

$45.38 USD

45.38
37,372,119

-1.84 (-3.90%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $45.50 +0.12 (0.26%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (90 out of 246)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Lilly's (LLY) Tirzepatide Meets Endpoints in Late-Stage Study

by Zacks Equity Research

Lilly's (LLY) tirzepatide demonstrates superiority in improving blood sugar levels and reducing body-weight compared to placebo in a phase III study evaluating in type 2 diabetes patients.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Alibaba, QUALCOMM, Novo Nordisk, Boeing and Delta Air Lines

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Alibaba, QUALCOMM, Novo Nordisk, Boeing and Delta Air Lines

Zacks Equity Research

Aligos (ALGS) Inks Collaboration With Merck for NASH Therapy

by Zacks Equity Research

Aligos (ALGS) signs an exclusive research collaboration agreement with Merck to discover and develop an oligonucleotide therapy for NASH. Shares rise.

Sheraz Mian headshot

Top Research Reports for Alibaba, QUALCOMM & Novo Nordisk

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Alibaba Group Holding Limited (BABA), QUALCOMM Incorporated (QCOM) and Novo Nordisk AS (NVO).

Zacks Equity Research

FDA Approves Label Expannsion of Novo Nordisk's (NVO) Saxenda

by Zacks Equity Research

Novo Nordisk (NVO) gets FDA approval for an updated label for Saxenda (liraglutide) injection 3 mg.

Zacks Equity Research

Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?

by Zacks Equity Research

Sector ETF report for PPH

Zacks Equity Research

AstraZeneca (AZN) Forxiga Approved in Japan for Heart Failure

by Zacks Equity Research

AstraZeneca (AZN) Forxiga is approved in Japan for chronic heart failure (HF) in patients who are receiving standard of care.

Zacks Equity Research

Is Novo Nordisk (NVO) a Suitable Stock for Value Investors?

by Zacks Equity Research

Let's see if Novo Nordisk A/S (NVO) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

Zacks Equity Research

Novo Nordisk's (NVO) Phase IIIb Study Meets Primary Endpoint

by Zacks Equity Research

Novo Nordisk's (NVO) semaglutide 2.0 mg demonstrates superior reduction in HbA1c versus once-weekly semaglutide 1.0 mg in people with type II diabetes.

Zacks Equity Research

Gilead (GILD), Novo Nordisk Post Upbeat Data From NASH Study

by Zacks Equity Research

Gilead (GILD) and Novo Nordisk present favorable outcomes from a mid-stage study in NASH patients.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Facebook, Verizon, Toyota Motor, Novo Nordisk, Applied Materials and General Motors

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Facebook, Verizon, Toyota Motor, Novo Nordisk, Applied Materials and General Motors

Sheraz Mian headshot

Top Research Reports for Facebook, Verizon & Toyota Motor

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Facebook (FB), Verizon Communications (VZ) and Toyota Motor (TM).

Zacks Equity Research

Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?

by Zacks Equity Research

Sector ETF report for PPH

Zacks Equity Research

Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?

by Zacks Equity Research

Sector ETF report for PPH

Zacks Equity Research

Novo Nordisk (NVO) Catches Eye: Stock Jumps 7.2%

by Zacks Equity Research

Novo Nordisk (NVO) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Zacks Equity Research

Novo Nordisk's (NVO) Q3 Earnings Beat Estimates, Sales Miss

by Zacks Equity Research

Novo Nordisk (NVO) misses earnings and sales estimates in the third quarter of 2020.

Zacks Equity Research

SNY or NVO: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

SNY vs. NVO: Which Stock Is the Better Value Option?

Zacks Equity Research

Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?

by Zacks Equity Research

Sector ETF report for PPH

Sheraz Mian headshot

Q3 Earnings Scorecard and Top Research Reports for Apple, PepsiCo & McDonald's

by Sheraz Mian

Today's Research Daily features Q3 earnings season scorecard and new research reports on Apple (AAPL), PepsiCo (PEP) and McDonald's (MCD) and others.

Kinjel Shah headshot

Pharma Stock Roundup: LLY, AZN, PFE, GSK Progress on Coronavirus Programs

by Kinjel Shah

Lilly (LLY), Pfizer (PFE) and AstraZeneca (AZN) provide updates on their coronavirus vaccine/treatment programs.

Zacks Equity Research

Novo Nordisk Raises Sales & Operating Profit Outlook for 2020

by Zacks Equity Research

Novo Nordisk (NVO) raises 2020 sales and operating profit outlook at constant exchange rates.

Zacks Equity Research

The Zacks Analyst Blog Highlights: JPM, PYPL, NVO, RHHBY and TM

by Zacks Equity Research

The Zacks Analyst Blog Highlights: JPM, PYPL, NVO, RHHBY and TM

Zacks Equity Research

SNY vs. NVO: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

SNY vs. NVO: Which Stock Is the Better Value Option?

Sheraz Mian headshot

Top Analyst Reports for JPMorgan, PayPal & Novo Nordisk

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase (JPM), PayPal (PYPL) and Novo Nordisk (NVO).

Zacks Equity Research

Lilly Drug Gets Fast Track to Improve Heart Attack Outcome

by Zacks Equity Research

Lilly's (LLY) EMPACT-MI study is part of Jardiance's ENPOWER clinical program, which is studying the impact of Jardiance on major clinical cardiovascular and renal outcomes in a spectrum of cardio-renal-metabolic conditions.